Your in-tray really is getting fuller
This article was originally published in SRA
You probably knew it anyway but now you have the evidence: the workload of regulatory affairs professionals in the pharmaceutical and biotech industries has “dramatically increased” in recent years, the Tufts Center for the Study of Drug Development in the US has confirmed.
You may also be interested in...
Another three marketing authorization applications will be fast-tracked through the centralized review process at the European Medicines Agency. The Pink Sheet tracker logs these and other developments relating to the agency's accelerated assessment mechanism.
The sponsors of up to seven new drugs or vaccines will find out this week whether their products will soon be approved in the EU. The products include two vaccines from Sanofi and what is possibly the first generic rival to Bayer's Xarelto to be assessed by the European Medicines Agency.
Takeda will soon seek EU approval of its dengue vaccine candidate. The marketing application will be fast-tracked, as will the applications for Regeneron's evinacumab and bluebird bio's eli-cel Lenti-D gene therapy.